AJJ Medtech reported FY 2025 revenue of SGD 3.2 million (up 37.4%) and a net loss attributable to equity holders of SGD 2.9 million for the 12 months ended 31 December 2025, with basic loss per share of 0.192 cents. Gross profit was SGD 1.2 million (up 100.2%). For Q4 2025, revenue was SGD 0.9 million (up 39.4%) and net loss attributable to equity holders was SGD 1.2 million, with basic loss per share of 0.080 cents. As at 31 December 2025, the group had cash and cash equivalents of SGD 414,000, total assets of SGD 3.6 million and total liabilities of SGD 6.3 million, with net liabilities of SGD 2.7 million and net asset value per share of (0.1585) cents. No dividend was declared or recommended. Management said the healthcare sector continued to face cost pressures, and highlighted supply chain diversification and disciplined inventory management, alongside a smart elderly care robotics joint venture roadmap with Huaxi Intelligent Technology for medical-grade humanoid eldercare robots and long-term medical consumables supply contracts with key healthcare networks. The company also cited revenue secured from public healthcare institution contracts via AJJ Healthcare as a key factor for the next 12 months, subject to execution, regulatory approvals and pipeline conversion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AJJ Medtech Holdings Ltd published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: TC58ITM2FUFVTXUY) on February 27, 2026, and is solely responsible for the information contained therein.